Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients
- PMID: 3897260
- DOI: 10.1210/jcem-61-4-753
Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients
Abstract
We studied two obese type II diabetic patients before, during, and after 3 yr of continuous iv insulin infusion, delivered by means of totally implanted insulin infusion pumps. Tolerance of the devices was excellent, and no side-effects or episodes of significant hypoglycemia occurred. Glycosuria was eliminated, and mean 24-h plasma glucose and hemoglobin A1c levels decreased in both patients and remained in or near the normal range for 3 yr. Improvements were also noted in serum triglyceride concentrations and vitreous fluorescein concentrations after iv fluorescein injection. Euglycemic insulin clamp studies showed that no significant change in glucose disposal rate occurred after 6 and 12 months of treatment. However, some improvement in insulin secretion during hyperglycemic insulin clamp studies occurred in both patients after 6 months of insulin infusion. Evaluation of the insulin-glycerol mixture used in the pump revealed that moderate degradation of insulin occurred in the pump during the 21-day flow cycle, resulting in 6-12% increases in fasting blood glucose levels; in addition, higher mol wt species of immunoreactive insulin were present in the patients' serum. We conclude that long term continuous iv infusion of insulin using a totally implantable infusion pump is practical in type II diabetic patients, is acceptable to patients, and is capable of providing near-normal glycemic control.
Similar articles
-
Basal-rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. A prospective crossover trial.Diabetes Care. 1989 Jul-Aug;12(7):455-63. doi: 10.2337/diacare.12.7.455. Diabetes Care. 1989. PMID: 2667926 Clinical Trial.
-
Glucose disposal in obese non-diabetic and diabetic type II patients. A study by indirect calorimetry and euglycemic insulin clamp.Diabete Metab. 1988 Jul-Aug;14(4):443-51. Diabete Metab. 1988. PMID: 3066652
-
Naloxone effects on post-prandial glucose, insulin and C-peptide levels in obese subjects.Diabetes Res. 1993;23(2):83-91. Diabetes Res. 1993. PMID: 7712683
-
Advantageous metabolic effects of pulsatile insulin delivery in noninsulin-dependent diabetic patients.J Clin Endocrinol Metab. 1988 Nov;67(5):1005-10. doi: 10.1210/jcem-67-5-1005. J Clin Endocrinol Metab. 1988. PMID: 3053747
-
Why intraperitoneal delivery of insulin with implantable pumps in NIDDM?Diabetes. 1992 Jun;41(6):657-61. doi: 10.2337/diab.41.6.657. Diabetes. 1992. PMID: 1587393 Review.
Cited by
-
Artificial pancreas: past, present, future.Diabetes. 2011 Nov;60(11):2672-82. doi: 10.2337/db11-0654. Diabetes. 2011. PMID: 22025773 Free PMC article. Review. No abstract available.
-
Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons.J Diabetes Sci Technol. 2008 Jul;2(4):735-8. doi: 10.1177/193229680800200429. J Diabetes Sci Technol. 2008. PMID: 19885254 Free PMC article.
-
Therapeutic dilemmas in type II diabetes mellitus--improving and maintaining beta-cell and insulin sensitivity.West J Med. 1988 Jun;148(6):685-90. West J Med. 1988. PMID: 3051674 Free PMC article. Review.
-
Long-term intraperitoneal insulin delivery.Ann Surg. 1992 Oct;216(4):483-91; discussion 491-2. doi: 10.1097/00000658-199210000-00011. Ann Surg. 1992. PMID: 1417197 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical